Near-term, the firm is focused on its cost structure and growing its top line with a view to becoming profitable, according to its interim CEO.
Helomics' managing executives will remain to manage TumorGenesis, Precision's newly formed subsidiary for cancer diagnostics and therapy.
The deal is the first for Hong Kong-based Prenetics and marks its foray into the consumer genomics space.
Roche noted that Flatiron partners with more than 265 community cancer clinics, six major academic research centers, and 14 therapeutic oncology companies.
Element Genomics' technology will increase UCB's pipeline, focusing on target discovery and interpretation in disease relevant systems.
Thompson Street will acquire YX Genomics Holding, the holding company of Transnetyx and two other subsidiaries.
The company will use a portion of the credit facility to fund its announced acquisition of Integrated DNA Technologies.
The company had intended to raise up to €6.6 million through the placement to help fund its planned acquisition of TGR Biosciences.
Sygnis said that TGR is profitable and has a complementary product portfolio that includes protein capture technology.
Thermo Fisher said that IntegenX complements and enhances its existing human identification product portfolio.
Bloomberg reports that the DNA-for-cash deal reported in Kentucky might be a more widespread scam.
St. Jude Children's Research Hospital scientists have treated infants with X-linked severe combined immunodeficiency using gene therapy in an early phase study.
St. Louis Public Radio reports that some African Americans are turning to DNA ancestry testing to help guide genealogical searches.
In Nature this week: a genomic analysis of the snailfish Pseudoliparis swirei, ancient DNA analysis gives insight into the introduction of farming to England, and more.